Individualizing chemotherapy for non-small cell lung cancer (NSCLC) in the adjuvant and advanced setting: Current status and future directions

Current Treatment Options in Oncology

Volumn 9, Issue 4-6, 2008, Pages 300-312

  Simon, George R ^a  

^a Thoracic Oncology Program for Chase Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MESSENGER RNA; NAVELBINE; OLIGONUCLEOTIDE; PACLITAXEL; PEMETREXED; PROTEIN P27; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M SUBUNIT 1; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; FUNCTIONAL PROTEOMICS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC IDENTIFICATION; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TREATMENT RESPONSE; BIOLOGICAL MODEL; CANCER STAGING; DISEASE FREE SURVIVAL; FORECASTING; GENETICS; LUNG TUMOR; MORTALITY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TIME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FORECASTING; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MODELS, GENETIC; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 70249114470     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-008-0075-z     Document Type: Review

References (39)

1. Bepler G, Begum M, Simon GR. Molecular analysis-based treatment strategies for non-small cell lung cancer. Cancer Control 2008;15:130-9.
2. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97. doi: 10.1056/NEJMoa043623
3. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60. doi: 10.1056/NEJMoa031644
4. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9. doi: 10.1200/JCO.2007.13.9030
5. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358:1118-28. doi: 10.1056/NEJMoa0706550
6. Hoeijmakers JH. Nucleotide excision repair I: From E. coli to yeast. Trends Genet 1993;9:173-7. doi: 10.1016/0168-9525(93)90164-D
7. Simon GR, Begum M, Bepler G. Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer. Future Oncol 2008;4:51-9. doi: 10.2217/14796694.4.1.51
8. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005;127:978-83. doi: 10.1378/chest.127.3.978
9. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-91. doi: 10.1056/NEJMoa060570
10. Filipits M, Pirker R, Dunant A, et al. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: The International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 2007;25:2735-40. doi: 10.1200/ JCO.2006.08.2867
11. Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;57:3381-5.
12. Elledge SJ, Zhou Z, Allen JB. Ribonucleotide reductase: Regulation, regulation, regulation. Trends Biochem Sci 1992;17:119-23. doi: 10.1016/ 0968-0004(92)90249-9
13. Gautam A, Bepler G. Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res 2006;66:6497-502. doi: 10.1158/0008-5472.CAN-05-4462
14. Bepler G, Gautam A, McIntyre LM, et al. 2002 Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol 20:1353-60. doi: 10.1200/ JCO.20.5.1353
15. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006;24:4731-7. doi: 10.1200/JCO.2006.06.1101
16. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-8. doi: 10.1056/NEJMoa065411
17. Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 2005;50:211-9. doi: 10.1016/j.lungcan.2005.06.013
18. Rosell R, Skrzypski M, Jassem E, et al. 2007 BRCA1: A novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2:e1129. doi: 10.1371/journal.pone.0001129
19. Wang L, Wei J, Qian X, et al. 2008 ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 8:97. doi: 10.1186/1471-2407-8-97
20. Cobo M, Massuti B, Moran T, et al. (2008) Spanish customized adjuvant trial (SCAT) based on BRCA1 mRNA levels. J Clin Oncol 26:S20. doi: 10.1200/JCO.2007.11.6905
21. Gan PP, Pasquier E, Kavallaris M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 2007;67:9356-63. doi: 10.1158/0008-5472.CAN-07-0509
22. Seve P, Lai R, Ding K, et al. 2007 Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of NCIC JBR.10. Clin Cancer Res 13:994-9. doi: 10.1158/1078-0432.CCR-06-1503
23. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80. doi: 10.1056/NEJMoa060467
24. Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20. doi: 10.1056/NEJMoa060096
25. Amann JM, Chaurand P, Gonzalez A, et al. Selective profiling of proteins in lung cancer cells from fine-needle aspirates by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Cancer Res 2006;12:5142-50. doi: 10.1158/1078-0432.CCR-06-0264
26. Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003;362:433-9. doi: 10.1016/ S0140-6736(03)14068-8
27. Schiller JH, Harrinton D, Sandler A, et al. 2000 A randomized phase III trial of four chemotherapy regimens in advanced Non-Small Cell Lung cancer(NSCLC). Proceedings of ASCO 19:1A.
28. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. doi: 10.1056/NEJMoa061884
29. Pirker R, Szczesna A, von Pawel J, et al. (2008) FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/ vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 26:1006s.
30. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 Expression Correlates with Prolonged Survival after Cisplatin plus Gemcitabine Chemotherapy in Non-Small Cell Lung Cancer. Clin Cancer Res 2002;8:2286-91.
31. Simon GR, Sharma A, Li X, et al.: Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007, (in press)
32. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer. J Clin Oncol 2007;25:2747-54. doi: 10.1200/JCO.2006.09.7915
33. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-96. doi: 10.1002/cncr.22208
34. Hanauske AR, Eismann U, Oberschmidt O, et al. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs 2007;25:417-23. doi: 10.1007/ s10637-007-9060-9
35. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97. doi: 10.1200/JCO.2004.08.163
36. Peterson P, Park K, Fossella F, et al. (2007) Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). Eur J Cancer 5:S4.
37. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51. doi: 10.1200/JCO.2007.15.0375
38. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-300. doi: 10.1038/nm1491
39. Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007;25:2741-6. doi: 10.1200/JCO.2006.08.2099